Quick Answer
Inhibikase Therapeutics, Inc. reported Common Stock Shares Outstanding of 131.69 million shares for the year ending 2025.
- Inhibikase Therapeutics, Inc. showed an increase of +89.9% in Common Stock Shares Outstanding from 2024 to 2025.
- This data is from Inhibikase Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 26, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2021: 10.06 million shares | Q2 2021: 25.13 million shares | Q3 2021: 25.16 million shares | Q1 2022: 25.23 million shares | Q2 2022: 25.23 million shares | Q3 2022: 25.23 million shares | Q1 2023: 31.06 million shares | Q2 2023: 5.29 million shares | Q3 2023: 5.36 million shares | Q1 2024: 6.48 million shares | Q2 2024: 7.22 million shares | Q3 2024: 7.46 million shares | Q1 2025: 74.34 million shares | Q2 2025: 74.52 million shares | Q3 2025: 74.81 million shares.
- Over the full 6 years of available data (2020 to 2025), Inhibikase Therapeutics, Inc.'s Common Stock Shares Outstanding has grown by 1,210.2%.
- Historical annual values: Fiscal year 2025: 131.69 million shares | Fiscal year 2024: 69.36 million shares | Fiscal year 2023: 6.19 million shares | Fiscal year 2022: 4.22 million shares | Fiscal year 2021: 25.16 million shares | Fiscal year 2020: 10.05 million shares.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: